A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)
PHASE1CompletedINTERVENTIONAL
Enrollment
13
Participants
Timeline
Start Date
Not specified
Study Completion Date
December 31, 1992
Conditions
HIV Infections
Interventions
BIOLOGICAL
HIVAC-1e
BIOLOGICAL
gp160 Vaccine (MicroGeneSys)
Trial Locations (1)
981050371
Children's Hospital & Medical Center / Seattle ACTU, Seattle
All Listed Sponsors
lead
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
NCT00000631 - A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn) | Biotech Hunter | Biotech Hunter